Navigation Links
Cornerstone Pharmaceuticals' Cancer Metabolism Inhibitor, CPI-613, Showing Promise in Phase I Trial for Acute Myeloid Leukemia
Date:12/12/2011

be diagnosed with acute myeloid leukemia in 2011. Chemotherapy is the standard of treatment for untreated adult.  Cornerstone's CPI-613 may represent a potential new alternative treatment for this disease.

"This study demonstrates early proof of concept for this class of agents, which is very important because relatively few treatment options exist for patients with myeloid leukemia, especially with relapsed/refractory disease," said the CEO of Cornerstone Pharmaceuticals, Robert Shorr, Ph.D. "Preliminary results from the ongoing Phase I study demonstrate the safety of this first-in-class agent, CPI-613, with very few adverse events, and support further exploration of CPI-613 as a potential treatment for AML and other hematologic malignancies."

The CPI-613 poster session, "Altered Lipid and Mitochondrial Metabolism Are Viable Targets in Acute Leukemia" (http://bit.ly/scSBqO) is scheduled for December 12 from 6 p.m. to 8 p.m. at Hall GH (San Diego Convention Center).

About CPI-613

CPI-613 is the first drug in a new chemical class that, through a novel mechanism, targets metabolic changes considered to be common to many, if not all, cancer types and not present in normal cells. Patients with solid tumors and hematologic cancers are currently being treated in multiple Phase I and Phase I/II human clinical trials evaluating CPI-613. These trials include a Phase I/II single agent trial for patients with solid tumors who have failed all other therapy options, a Phase I/II combination trial with gemcitabine in newly diagnosed or relapsed patients, and a single agent trial in hematologic malignancies. CPI-613 was granted orphan drug status by the US FDA for pancreatic cancer and for AML.

About Cor
'/>"/>

SOURCE Cornerstone Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
2. Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
3. Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
4. Cornerstone Therapeutics to Present at the 30th Annual Cowen & Company Health Care Conference
5. Cornerstone Therapeutics to Host First Quarter 2010 Conference Call
6. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
7. Cornerstone Therapeutics Announces Management Change
8. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
9. Cornerstone Therapeutics Announces Collaboration with The Cough Company
10. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
11. Cornerstone Therapeutics Announces Development of Generic for Tussionex®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  Commonwealth Cornerstone Group (CCG) today announced the ... on Tuesday to help fund the expansion and consolidation of ... Sharon . PHN is the ... . It is the largest employer in ... people on staff. Currently, PHN Sharon offers scattered ...
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission ... ResMed (RMD) against BMC Medical. In a notice issued on ... found that ResMed,s patent on its humidifier was invalid. ... a "monumental win". "We are very excited with the ITC,s ... position that we have taken since the very beginning on ...
(Date:12/24/2014)... YORK and LONDON , ... global orthopedic industry are expected to grow at an ... in terms of value and volume. Hip, knee and ... developed world while in emerging economies they have a ... rates are challenging the use of composites. Non-metallic orthopedic ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... 25 LigoCyte Pharmaceuticals, Inc. , a ... today announced positive results from a Phase I/II ... vaccine candidate. Baylor College of Medicine,s Robert Atmar, ... the trial via an oral presentation at the ...
... Oct. 25 Express Scripts, Inc. (Nasdaq: ... following investor conferences in November:Oppenheimer 21st Annual Healthcare Conference ... Suisse 2010 Healthcare Conference on Wednesday, November 10, 2010 ... 7th Annual Healthcare Conference on Tuesday, November 16, 2010 ...
Cached Medicine Technology:Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting 2Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting 3Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting 4Express Scripts to Present at Investor Conferences in November 2
(Date:12/26/2014)... 26, 2014 Yisrayl Hawkins, Pastor at The ... letter in light of the Ferguson, Missouri unrest. Yisrayl starts ... unrest and explains why it has only increased. , ... even created. He says there is a very specific reason ... says there is a set of rules, or Laws that ...
(Date:12/26/2014)... Orlando, FL (PRWEB) December 26, 2014 ... visitor health insurance in the USA, announced today a ... to assist members in choosing the right plan for ... take the complexity out of the selection process when ... premiums by age group with only a few clicks. ...
(Date:12/25/2014)... The microscopy market is estimated to grow at ... by 2019. Optical microscopy is the largest segment ... segment is expected to show the fastest growth ... nanotechnology, technological advancements, and increasing federal support to ... Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... 26, 2014 The report “TS-1 (Colorectal ... on the current treatment landscape, unmet needs, current pipeline ... is an anti-cancer drug which is typically used for ... also used for treating gastric cancer and pancreatic cancer. ... The drug was first approved in 1999 in Japan ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying women’s ... discounted prom dresses, most of which are priced under ... company, the promotion is valid until Jan. 22, 2015; ... UK market. , The prom dresses in this new ... A-line strapless, empire strapless chiffon, one shoulder, floor-length, V-neck ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... The Damon Runyon Cancer Research Foundation named ... April 2010 Clinical Investigator Award Committee review. ... outstanding early career physician-scientists conducting patient-oriented cancer research ... the nation,s leading scientists and clinicians. Each will ...
... new magnetic resonance imaging technology that could revolutionise the ... take a major step forward as a 7m research ... Hyperpolarisation with parahydrogen is a technique developed at the ... resonance imaging (MRI), the scanning technology widely used in ...
... ... release of their new Alpha 3C™ formula, designed to naturally support focus, calmness ... ... of premium dietary supplements, announces the release of their new Alpha 3C™ formula, ...
... therapy made from a human protein significantly decreases disease ... a new asthma therapy for patients who do not ... in an animal model were presented at The Endocrine ... protein, insulin-like growth factor binding protein-3 (IGFBP-3), uniquely inhibits ...
... ... order to attract patients, compete effectively, grow their revenues, counter the declining economy and ... ... doctor and physician marketing firm Heathcare Success Strategies , doctors are increasingly resorting ...
... ... achieve greater athletic outcomes and increase their performance. , ... Pittsburgh, PA (PRWEB) June 28, ... premiere health care facilities, is an organization of physicians and health care professionals ...
Cached Medicine News:Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 2Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 3Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 4Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 5Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 6Health News:New scanning technology developed in £7M research center 2Health News:Purity Products Releases Alpha 3C 2Health News:Experimental nonsteroidal treatment of asthma shows promise 2Health News:Doctors and Medical Groups Increasingly Embrace Physician Marketing to Counter Changes in Health Care 2Health News:Allegheny Medical's SportsCare Programs Combine Lifestyle, Fitness and Behavior Management with Quality Medical Treatments 2
... offers three-dimensional VCS technology, ... and efficiency in white ... analysis. With its reputation ... HmX is an affordable ...
... LH 755 simplifies and automates ... expert automation and advanced technologies ... reliable, accurate results every time. ... slide quality with its slide-on-slide ...
... CKX microscopes utilize the infinity-corrected ... and operability in cell checking. ... inverted microscope suited to routine ... fields--from tissue culture and embryology ...
... was designed from the ground-up with ergonomic ... height and most adjustable observation tube on ... that every user can adjust the microscope ... flexibility helps the operator maintain an upright, ...
Medicine Products: